Welcome Message
On behalf of the Organizing Committee, we take great pleasure in
welcoming Scientists, Professors, Students and experts who belong to the Pulmonology field for the 11th
International Conference on COPD and Lung Health which is scheduled during
October 11-12, 2023 at Paris, France.
COPD 2023 unites the
worldwide pioneers who are involved in the Pulmonary and respiratory field to
explore their research work in the conference. COPD 2023 provides a great chance
to collaborate with global business delegates and researchers and it is all set
to be adorned by world renowned speakers.
With the successful completion of COPD 2022, which was held during
November 22-23 ,2022, Webinar with the theme “Coronavirus and
the outbreak of the respiratory illness - COPD 2022”, we are back with
CPD Accredited 11th International Conference on COPD and Lung Health with the
theme “Care for Your Lungs: Breathe Well, Live Healthier”. The wide range of topics will give
attendees a chance to learn about every aspect of COPD and respiratory
diseases.
Abstract Submission
Abstract Submission
Guidelines:
Ø Abstract length must not
exceed 300 words.
Ø The title should be in
sentence case.
Ø Mention the full name of
the author and co-authors (if any) along with affiliation.
Ø It should contain short
biography of the author (limited to 100 words) along with the photograph.
Ø All the abstracts will be
reviewed by the scientific committee members and you will get an email within
24-48 hours after submission of your abstract.
Ø All the accepted abstracts
will be published in the conference proceedings in the respective Journal.
Abstract Submission URL: https://copd.alliedacademies.com/abstract-submission
Registration URL: https://copd.alliedacademies.com/registration
Sessions and Tracks
Session Track 1: COPD
Chronic
Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage
and problems related to breathing. It can cause coughing that produces large amounts of a
slimy substance called mucus, wheezing, shortness of breath as well as chest
tightness. Cigarette smoking is the leading cause of COPD.
Long-term exposure to various lung irritants such as air pollution, chemical
fumes, or dusts also contribute to COPD. A rare genetic condition called
alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be
cured but it can be treated to lower the chance of complications, and generally
improve quality of life. Clinical symptoms and signs, such as abnormal
shortness of breath and increased forced expiratory time, can be used to help
with the diagnosis of COPD. Various forms of treatment include Medications,
supplemental oxygen
therapy and surgery.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 2: Respiratory Diseases
Respiratory diseases encompass a variety of pathogenic
conditions that affect respiration in living organisms. Respiration involves
gas exchange in higher organisms. Respiratory disorders occur in the
respiratory tract, which includes the alveoli, bronchi, bronchioles, pleura, pleural
cavity, trachea and the nerves and muscles of breathing. Respiratory diseases
or lung diseases include COPD, asthma, cystic fibrosis, emphysema, lung
cancer, interstitial lung disease,
mesothelioma, pulmonary hypertension, tuberculosis, alpha-1 antitrypsin deficiency,
bronchiectasis, idiopathic pulmonary fibrosis, pneumonia, respiratory failure,
respiratory distress syndrome, sarcoidosis, sleep apnea, sleep deprivation and
deficiency, influenza and many more. If left untreated, they lead to health
complications and life-threatening conditions.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 3: Effect of COVID – 19 on Lungs
COVID-19 is a respiratory disease which causes a range of breathing
problems, from mild to critical. Older adults and people who have other health
conditions like heart disease, cancer, and diabetes may have more serious
symptoms when compared to others. Coronavirus can infect the upper or lower part
of the respiratory tract and travels down the airways making the lining become
irritated and inflamed. In some cases, the infection can reach all the way down into the
alveoli. Respiratory inflammation can be observed on a chest X-ray or CT scan. Currently, convalescent plasma from a
recovered patient is given by transfusion to a patient who is suffering from
COVID-19. The donor antibodies may help the patient fight the illness, possibly
shortening the reducing the severity of the disease.
Related Keywords : COPD
Conferences | Conferences on Lung Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session
Track 4: Bronchoscopy
Bronchoscopy is an endoscopic procedure of
envisioning the inside of the air passages for diagnostic and therapeutic
purposes. An instrument (bronchoscope) is inserted into the airways,
consistently through the nose or mouth, or seldom through a tracheostomy. This allows the specialist to examine
the patient's airways for abnormalities such as foreign bodies, bleeding, tumors, or inflammation. Specimens may be taken
from inside the lungs. The construction of bronchoscopes ranges from rigid
metal tubes with attached lighting devices to flexible optical fiber
instruments with Real time video equipment.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session 5: Pulmonary Rehabilitation
Pulmonary
Rehabilitation is an exclusive program for education and
exercise that helps to manage the breathing problems, increase the alveolar
capacity for breathing and the energy of the individual and reduces the
breathlessness. Pulmonary rehabilitation can help to gain strength, reduce
symptoms of anxiety or depression, and make it easier to manage routine activities, work,
and outings or social activities.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session
6: Lung Cancer Diagnosis & Treatment
Lung
cancer is a condition that causes
cells to divide in the lungs uncontrollably which leads to the growth of tumors
that reduce a person's ability to breathe. Symptoms of lung cancer include appetite loss, changes to a person's voice, such
as hoarseness, frequent chest infections, such as bronchitis or pneumonia, lingering cough that may start to get
worse, shortness of breath, unexplained headaches, weight loss and wheezing.
Early diagnosis of lung cancer can be lifesaving because lung cancer cells can
travel to other areas of the body before a doctor detects them in the lungs. If
metastasis has taken place, it makes treating the disease much more difficult.
Treatment for lung cancer depends on its location and stage, as well as the
overall health of the individual. Possible treatments include surgery, chemotherapy, radiation therapy and targeted
therapy.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session 7: Noninvasive
Ventilatory Support
Non-invasive ventilation (NIV) is the delivery of oxygen
(ventilation support) via a face mask and therefore eradicating the need of an
endotracheal airway. NIV achieves comparative physiological benefits to
conventional mechanical ventilation by decreasing the work of breathing and
improving gas exchange. Research suggests that non-invasive ventilation after
early extubation looks helpful in reducing the total days spent on invasive
mechanical ventilation. The intervention is recognised as an adequate treatment
for respiratory failure in chronic obstructive
pulmonary disease, cardiogenic pulmonary oedema and other respiratory
conditions without complications such as respiratory muscle weakness, upper
airway trauma, ventilator-associated pneumonia, and sinusitis.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session 8: Imaging in
Pulmonary Hypertension
Pulmonary hypertension is a complex pathophysiologic condition in which several
clinical realities increase pressure in the pulmonary rotation, precipitously injuring cardiopulmonary function and, if undressed, causing right ventricular
failure. The major role of imaging is to establish the diagnosis of PH and
classify the PH into one of the five groups. Imaging is also used in the quantification of volumes and
function, which is necessary for prognosis, therapy, and assessing response to
treatment.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 9: Digital health for COPD Care
Engaging chronic obstructive pulmonary disease (COPD) patients to actively engage in self-management has proven difficult. Digital health technology (DHT) promises to expedite a patient-centred care model for the management of COPD by empowering patients to self-manage adequately. The emerging approaches included digital-technology-enabled homecare programs, electronic records, big data analytics, and environment-monitoring applications. The digital health approaches of telemonitoring, telehealth and mHealth support the self-management, post-discharge care, and hospital-at-home strategy, with eventual effects on reducing acute COPD exacerbations and hospitalizations.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session
Track 10: Interventional
Pulmonology
Interventional pulmonology (IP) uses basic invasive procedures to diagnose and
treat lung cancer, pleural diseases, and many types of complex airway and lung disorders.
Techniques for interventional pulmonology include:
• Flexible
bronchoscopy
• Bronchoalveolar
lavage
• Biopsy
of lung or lymph node
• Airway
stent (bronchial stent)
• Balloon bronchoplasty
• Rigid
bronchoscopy
• Foreign
body removal
• Thoracentesis
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 11: Interstitial Lung Disease
Interstitial lung disease characterizes a large
group of disorders, most of which cause progressive scarring of lung tissue.
The scarring correlated with interstitial lung disease basically affects your ability
to breathe and get enough oxygen into your bloodstream. Interstitial lung
disease can be induced by long-term exposure to hazardous materials, such as
asbestos. Some types of autoimmune diseases, such as rheumatoid
arthritis, also can cause interstitial
lung disease.
Types of Interstitial lung disease:
• Interstitial
pneumonia
• Idiopathic
pulmonary
fibrosis
• Hypersensitivity
pneumonitis
• Asbestosis
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 12: Tuberculosis
Tuberculosis (TB) is a serious infectious
disease that mainly affects the lungs and it is caused by bacteria
(Mycobacterium tuberculosis). The bacteria responsible for tuberculosis is
spread from one person to another through tiny droplets released into the air
via cough and sneeze. Tuberculosis can be fatal when it is untreated. Untreated
active disease typically affects the lungs, and it can spread to other parts of
the body through the blood stream. Complications of tuberculosis include spinal
pain, joint damage, swelling of the membranes that cover the brain, liver or
kidney problems and heart disorders. People diagnosed with active TB disease
generally have to take a combination of medications for six to nine months. A
significant number of TB patients develop post tubercular airway disease or
TB-associated COPD.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 13: Asthma
Asthma is a clinical syndrome of chronic airway inflammation characterized by recurrent and reversible airway obstruction. Most people with asthma will not develop COPD, However, it’s possible to have both. Asthma-COPD overlap syndrome (ACOS) occurs when someone has these two diseases at a time. Signs of ACOS include difficulty in breathing, wheezing, frequent coughing, excess phlegm, feeling tired, low physical tolerance for exercise, shortness of breath during routine activities. Common triggers for asthmatic symptoms include exposure to allergens (dust mites, cockroach, molds and pollens), exercise and viral infections. Most people who have asthma are treated with daily medicine, called long-term control medicines, along with inhalers containing medicine for short-term relief.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 14: Pneumonia
Pneumonia is an infection that inflames the
air sacs in the lungs and people with COPD are more likely to develop
pneumonia. It is most serious for infants, young children and older people
whose age is above 65, and people with weakened immune systems. Bacterial pneumonia, is the most common form, tends
to be more serious than other types of pneumonia. The symptoms of bacterial
pneumonia can develop gradually. In few cases pneumonia can be difficult to
diagnose because the symptoms are so variable and are often very similar to
those seen in a cold or influenza. Complications of pneumonia are as follows:
pleural effusion, empyema, lung abscess, bacteremia, septicemia, meningitis,
septic arthritis, endocarditis, or pericarditis.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 15: Sleep Apnea
Sleep
apnea is a sleep disorder
that occurs when a person's breathing is interrupted during sleep. If left
untreated, sleep apnea can increase the risk of health problems, such as high
blood pressure, stroke, heart failure, irregular heartbeats, and heart
attacks, diabetes, depression, worsening of ADHD, headaches.
Depending on the cause and the level of apnea, there are different methods of
treatment and the goal of treatment is to normalize breathing during sleep.
Treatment options for obstructive sleep apnea include: Continuous Positive Airflow
Pressure (CPAP), other
breathing devices, oral appliances, implants and surgery.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 16: Cystic Fibrosis
Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time and it affects the cells that produce mucus, sweat and digestive juices. It is caused by a change, or mutation, in a gene called CFTR (cystic fibrosis trans membrane conductance regulator). This gene controls the flow of salt and fluids in and out of the cells. The thick and sticky mucus associated with cystic fibrosis clogs the tubes that carry air in and out of the lungs. This can cause signs and symptoms such as persistent cough that produces thick mucus, wheezing, breathlessness, exercise intolerance, repeated lung infections, inflamed nasal passages or a stuffy nose. Cystic fibrosis is one of the leading causes of bronchiectasis, a condition that damages the airways and this makes it harder to move air in and out of the lungs and clear mucus from the airways.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session
Track 17: COPD and
Alpha-1 antitrypsin
Alpha-1 antitrypsin
deficiency is a genetic disorder
that is passed on in families and affects the lungs, liver and skin. When this
condition affects the lungs, it causes COPD. There is no cure, but treatment
can help people with Alpha-1 antitrypsin deficiency manage their symptoms and
live a better life. The preliminary symptoms are shortness of breath following
mild activity, reduced ability to exercise, and wheezing. Other signs and
symptoms include unintentional weight loss, recurring respiratory infections,
fatigue, and rapid heartbeat upon standing. Affected individuals often
develop emphysema, which is a lung disease caused by
damage to the small air sacs in the lungs. Alpha-1 antitrypsin deficiency
accounts for 1 to 2% of all cases of chronic
obstructive pulmonary disease.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Session Track 18: Diagnosis and Treatment of COPD
The main test for diagnosing COPD is a
lung function test called spirometry which involves the use of a machine called a spirometer that
measures how much air you are able to move by taking a deep breath in and out,
and how quickly you are able to do so. Arterial blood gas analysis is second
important test in diagnosing COPD. This test measures how much oxygen and
carbon dioxide are present in the blood. A high percentage of carbon dioxide in
the blood can be a sign of poorly functioning lungs. The important methods of
treatment are pharmacotherapy and smoking cessation, while pulmonary
rehabilitation, long-term oxygen therapy, and surgery may be considered in
selected patients. Steroids, inhalers and antibiotics may be
prescribed to treat various symptoms of COPD. Smoking cessation is the most effective intervention
in stopping the progression of COPD, as well as increasing survival rate of
persons suffering with COPD. Hence, smoking cessation should be the top
priority in the treatment of COPD.
Related Keywords : COPD
Conferences | Conferences on Lung
Health | Meetings
on Pulmonary Diseases | Pulmonology
Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung
Diseases | Respiratory Diseases | Pulmonology
Market Analysis
Globally, asthma and COPD are one of the leading chronic respiratory
diseases, with high prevalence and increasing health care and economic burden.
They are either genetically acquired or caused due to several environmental
factors. The global market for Asthma & COPD has been analyzed based on
drugs and devices which are used for these diseases. Currently, North America
leads the global market for asthma & COPD drugs and devices, and it was
followed by Europe in terms of market capitalization. Growing aging population
along with increasing automotive and industrial exhaust gases have remained the
key drivers for the global asthma and COPD market. Degrading air quality near
the industrial areas has led to the increased incidence of asthma in the
low-income population in the emerging economies of China, India, Brazil and
Russia.
COPD is rated to be the
fourth most common cause of mortality, and expected to reach third position by
2030, in case the risks such as smoking, pollution is not addressed. There is a
rise in the prevalence of asthma and COPD in both developed and developing
countries. In developed countries, the rise in prevalence is mainly due to
lifestyle change such as smoking, while in developing countries rise is
observed due to presence of most polluted cities in the world and inclusion of
smoking in day-to-day lifestyle. Global COPD drugs market size will grow by
almost USD 3.52 billion during 2019-2023, at a CAGR close to 4% due to the
success of combination therapies.
